Sangamo Therapeutics (SGMOQ) Cash from Operations (2010 - 2025)

Sangamo Therapeutics has reported Cash from Operations for 16 years, with the latest figure at -$24.4 million in Q4 2025.

• On a quarterly basis, Cash from Operations fell 628.23% year-over-year to -$24.4 million in Q4 2025; TTM through Dec 2025 was -$97.2 million, a 44.79% decrease from a year earlier, with the FY2025 full-year figure at -$97.2 million, down 44.79% from the prior year.
• Cash from Operations was -$24.4 million for Q4 2025 at Sangamo Therapeutics, up from -$28.5 million in the prior quarter.
• The five-year high for Cash from Operations was $11.8 million in Q3 2024, with the low at -$68.6 million in Q1 2021.
• Average Cash from Operations over 5 years is -$42.3 million, with a median of -$51.6 million recorded in 2021.
• The sharpest annual moves came in 2021 and 2024: Cash from Operations sank 1127.33% in 2021, then surged 124.86% in 2024.
• Over 5 years, Cash from Operations stood at -$52.7 million in 2021, then slipped by 8.22% to -$57.0 million in 2022, then advanced by 11.41% to -$50.5 million in 2023, then surged by 93.37% to -$3.4 million in 2024, then sank by 628.23% to -$24.4 million in 2025.
• The last three Cash from Operations figures came in at -$24.4 million (Q4 2025), -$28.5 million (Q3 2025), and -$18.2 million (Q2 2025), per Business Quant data.